Hülya Olmus

Gazi University, Engüri, Ankara, Turkey

Are you Hülya Olmus?

Claim your profile

Publications (3)7.28 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: In this study it was aimed to determine the adherence of Pseudomonas and Candida to contact lens surfaces, and to determine the difference in adherence between five contact lens types. Biofilm-negative control strains were also used to emphasize the difference between biofilm-positive and biofilm-negative strains in adherence. Five different soft contact lenses were used to investigate the adherence of Pseudomonas aeruginosa and Candida albicans strains. P. aeruginosa ATCC 27853, P. aeruginosa ATCC 10145, C.albicans ATCC 10231 standard strains and C. albicans clinical isolate were included in the study. Slime formation was investigated by two methods; modified Christensen macrotube method, and a modified microtiter plate test. P. aeruginosa and C. albicans slime formation on soft contact lenses was studied in adherence and separation phases. Pseudomonas and Candida suspensions were serially diluted and inoculated to blood agar and sabouraud dextrose agar surfaces respectively. After overnight incubation, the colonies were counted. Sterile unworn contact lenses were used as negative controls, and bacterial and fungal culture suspensions were used as positive controls. The experiments were conducted in three parallel series. The number of adherent Pseudomonas was as follows from high to low in polymacon, etafilcon A, hilafilcon, ocufilcon and lotrafilcon contact lenses respectively. However, the number of adherent yeast were determined higher in lotrafilcon and ocufilcon contact lenses, followed by hilafilcon, etafilcon A and polymacon contact lenses. Biofilm-negative Pseudomonas ATCC standard strain and Candida clinical isolate were used to confirm that the number of adherent cells were lower than the biofilm-positive ones. This study demonstrates that in addition to the contact lens properties, the microorganisms themselves and their interactions with the lens material also play an important role in adherence.
    Albrecht von Graæes Archiv für Ophthalmologie 04/2011; 249(4):559-64. · 1.93 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The efficacy of aromatase inhibitors incorporated in the ovarian stimulation protocols of poor-responder patients undergoing intracytoplasmic sperm injection-embryo transfer cycles was investigated. A total of 70 poor-responder patients were randomized into two groups on day 3 of their menstrual cycle. In Group A, an aromatase inhibitor (letrozole, 5 mg/day) was administered along with a fixed dosage (450 IU/day) of recombinant FSH (rFSH), whereas Group B were treated with the same rFSH dosage alone. A flexible regimen of gonadotrophin-releasing hormone antagonist was administered in both groups. The mean total dose of rFSH (2980 +/- 435 IU versus 3850 +/- 580 IU, P < 0.05) and serum concentrations of oestradiol on the day of human chorionic gonadotrophin administration (1870 +/- 159 pg/ml versus 2015 +/- 175 pg/ml, P < 0.05) were significantly lower in Group A compared with Group B, respectively. The rate of cycle cancellation due to poor ovarian response was lower in Group A (8.6%) than in Group B (28.6%), ( P < 0.05). The costs of achieving a clinical pregnancy were US$11560 and US$17584, and the clinical pregnancy rates per embryo transfer were 25.8% and 20%, in groups A and B, respectively. In conclusion, adjunctive letrozole administration seems to restore an IVF cycle by decreasing the rate of cycle cancellation and seems to reduce the cost by reducing the total gonadotrophin dosage.
    Reproductive biomedicine online 10/2009; 19(4):478-85. · 2.68 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The effect of dehydroepiandrosterone (DHEA) supplementation on cycle outcome was assessed in patients with poor ovarian response. In total, 19 poor responder patients who were scheduled to undergo a second intracytoplasmic sperm injection (ICSI)/embryo transfer cycle were enrolled and first ICSI/embryo transfer cycles were taken as the control group. All subjects were given DHEA supplementation (25 mg t.i.d.) for at least 3 months prior to their second ICSI/embryo transfer cycle. In both cycles a fixed dose of rFSH (300 IU/day) and human menopausal gonadotrophin (HMG) (75 or 150 IU/day) along with a flexible gonadotrophin-releasing hormone (GnRH) antagonist protocol were administered. A favourable decrease was noted in mean day 3 serum oestradiol concentrations after DHEA supplementation (75.14 +/- 28.93 versus 43.07 +/- 11.77; P < 0.01). Increased number of >17 mm follicles (3 +/- 0.7 versus 1.9 +/- 1.3; P < 0.05), MII oocytes (4 +/- 1.8 versus 2.1 +/- 1.8; P < 0.05), top quality day 2 (2.2 +/- 0.8 versus 1.3 +/- 1.1; P < 0.05) and day 3 embryos (1.9 +/- 0.8 versus 0.7 +/- 0.6; P < 0.05) were achieved in DHEA-supplemented cycles. Cycle cancellation rates were reduced (5.3% versus 42.1%; P < 0.01), and the pregnancy rate per patient and clinical pregnancy rate per embryo transfer (47.4% versus 10.5%; P < 0.01 and 44.4% versus 0%; P < 0.01) were improved after DHEA supplementation. DHEA supplementation might enhance ovarian response, reduce cycle cancellation rates and increase embryo quality in poor responders.
    Reproductive biomedicine online 10/2009; 19(4):508-13. · 2.68 Impact Factor

Publication Stats

37 Citations
7.28 Total Impact Points

Institutions

  • 2009
    • Gazi University
      • Department of Statistics
      Engüri, Ankara, Turkey
    • Ankara University
      • Department of Obstetrics and Gynecology
      Ankara, Ankara, Turkey